Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2015

View Archived Issues

Researchers discover genetic susceptibility locus associated with TB

Columbia University prepares and tests RBP4 antagonist for AMD

Adimab enters new antibody discovery collaboration with Celgene

GlaxoSmithKline reflects on milestones of first quarter 2015

La Jolla acquires rights to next-generation gentamicin derivatives, reprioritizes pipeline

Johnson & Johnson forges partnership to evaluate compassionate use of investigational drugs

Takeda and National Cancer Center of Japan collaborate to develop anticancer agents

Merck KGaA presents BTK inhibitors

Glenmark discloses mPGES-1 inhibitors

Data from clinical trials of GS-9857 support continued clinical evaluation

Same autoantibodies seen in retinitis pigmentosa models and patients with MERTK mutations

Prima BioMed enters Japanese collaboration for IMP-321

FDA accepts Gemmus' IND for GP-1681 to alleviate influenza symptoms

Formula Pharmaceuticals acquires rights to allogeneic non-viral CAR immunotherapy platform

FDA issues complete response letter for Invega Sustenna sNDA

Redx porcupine inhibitor achieves preclinical PoC

FDA approves Roche's KRAS mutation test for metastatic CRC

GSK and UNC-Chapel Hill form partnership to seek cure for HIV/AIDS

Mitsubishi Tanabe Pharma recaps highlights of fourth quarter of fiscal 2014

AbbVie patent reports development of GlyT-1 inhibitors

Janssen patents new anti-HBV compounds

Takeda discloses SSTR5 antagonists

Pre-amplification improves SNP genotype assays with hair and saliva samples

Ligand acquires rights to 15 full funded assets from Selexis

GB-232 begins phase I trial in South Korea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...